PAVmed Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

PAVmedDer Gewinn des Unternehmens wird voraussichtlich um 77.8% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 60.8% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-77.8%

Wachstumsrate der Gewinne

-81.5%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	60.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

Jul 05

Start Accumulating PAVmed

Dec 24

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

Sep 02

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Aug 23

PAVmed: A True Game-Changer For Medical Device Innovation

Jun 14

PAVmed forms digital health company, Veris Health

Jun 02

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

May 26

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

May 19

PAVmed drops 14% on launch of $13.4M direct offering

Jan 06

PAVmed closes additional direct offering of common stock

Dec 22

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

Dec 16

PAVmed offers stock for $8.9M

Dec 11

PAVmed EPS beats by $0.02

Nov 17

There Is Progress At PAVmed, But More Patience Is Required

Oct 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:PAVM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	51	-10	2	N/A	2
12/31/2025	16	-40	-32	-42	3
12/31/2024	3	29	-54	-48	1
9/30/2024	4	15	-45	-46	N/A
6/30/2024	4	-67	-48	-48	N/A
3/31/2024	3	-71	-49	-49	N/A
12/31/2023	2	-66	-52	-52	N/A
9/30/2023	2	-71	-57	-57	N/A
6/30/2023	1	-79	-69	-65	N/A
3/31/2023	1	-90	-79	-75	N/A
12/31/2022	0	-89	-76	-71	N/A
9/30/2022	1	-86	-79	-71	N/A
6/30/2022	1	-72	-64	-60	N/A
3/31/2022	1	-58	-48	-44	N/A
12/31/2021	1	-51	-44	-41	N/A
9/30/2021	0	-42	-31	-31	N/A
6/30/2021	N/A	-35	-29	-28	N/A
3/31/2021	N/A	-30	-27	-27	N/A
12/31/2020	N/A	-35	-22	-22	N/A
9/30/2020	N/A	-32	-19	-19	N/A
6/30/2020	N/A	-30	-16	-16	N/A
3/31/2020	N/A	-28	-13	-13	N/A
12/31/2019	N/A	-17	-13	-13	N/A
9/30/2019	N/A	-17	-12	-12	N/A
6/30/2019	N/A	-17	-11	-11	N/A
3/31/2019	N/A	-19	-10	-10	N/A
12/31/2018	N/A	-19	-9	-9	N/A
9/30/2018	N/A	-12	-7	-7	N/A
6/30/2018	N/A	-14	N/A	-8	N/A
3/31/2018	N/A	-10	N/A	-7	N/A
12/31/2017	N/A	-10	N/A	-7	N/A
9/30/2017	N/A	-12	N/A	-6	N/A
6/30/2017	N/A	-9	N/A	-5	N/A
3/31/2017	N/A	-9	N/A	-6	N/A
12/31/2016	N/A	-6	N/A	-4	N/A
9/30/2016	N/A	-5	N/A	-4	N/A
6/30/2016	N/A	-3	N/A	-3	N/A
3/31/2016	N/A	-2	N/A	-2	N/A
12/31/2015	N/A	-2	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PAVMFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-77.8% pro Jahr).

Ertrag vs. Markt: PAVMFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-77.8% pro Jahr).

Hohe Wachstumserträge: PAVMFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: PAVMDie Einnahmen des Unternehmens (60.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: PAVMDie Einnahmen des Unternehmens (60.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PAVM in 3 Jahren voraussichtlich hoch sein wird

PAVmed Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 11%, EPS upgraded

Consensus revenue estimates decrease by 16%, EPS upgraded

Consensus EPS estimates fall by 13%, revenue upgraded

Price target decreased by 21% to US$13.00

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 21% to US$16.38

Recent updates

New major risk - Revenue and earnings growth

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of ESOGUARD Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Consensus revenue estimates decrease by 11%, EPS upgraded

PAVmed Provides Update on Nasdaq Staff Determination Letter Regarding Non-Compliance with Market Value Under Listing Rule 5550(b)(2)

Consensus revenue estimates decrease by 16%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lucid Diagnostics Announces Positive Data from Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population

Insufficient new directors

New major risk - Market cap size

Consensus EPS estimates fall by 13%, revenue upgraded

Price target decreased by 21% to US$13.00

Pavmed Inc. Appoints Dennis Matheis to Board of Directors

PAVmed Inc., Annual General Meeting, Jun 20, 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 21% to US$16.38

Full year 2023 earnings: EPS exceeds analyst expectations

PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

PAVmed Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value of the Company’s Listed Securities Under Nasdaq Listing Rule 5550(b)(2)

New major risk - Share price stability

Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?

Now 24% undervalued after recent price drop

Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Price target decreased by 48% to US$20.63

Pavmed Inc. Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Pre Cancer Detection

Consensus revenue estimates decrease by 12%

New major risk - Negative shareholders equity

PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 35%

Consensus revenue estimates decrease by 40%, EPS upgraded

Consensus revenue estimates increase by 33%

No longer forecast to breakeven

PAVmed Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Independent Vice Chairman recently bought US$161k worth of stock

Price target decreased to US$5.06

Consensus forecasts updated

Consensus forecasts updated

Consensus revenue estimates fall by 80%

Price target decreased to US$5.50

Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?

PAVmed Non-GAAP EPS of -$0.17 beats by $0.03

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 2000 Dynamic Index

PAVmed Inc., Annual General Meeting, Jun 21, 2022

PAVmed Inc. announced delayed annual 10-K filing

Consensus revenue estimates fall by 10%

Price target decreased to US$8.13

PAVmed Inc. Appoints Shaun O’Neil as Executive Vice President and Chief Operating Officer

PAVmed Inc. Appoints Joan Harvey to Its Board of Directors

Start Accumulating PAVmed

Consensus forecasts updated

Price target increased to US$9.50

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Consensus revenue estimates fall to US$1.02m

Independent Director David Battleman has left the company

Independent Director David Weild has left the company

PAVmed: A True Game-Changer For Medical Device Innovation

Consensus forecasts updated

PAVmed forms digital health company, Veris Health

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $41.576088 million.

Price target raised to US$6.42

First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device

New 90-day high: US$2.68

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $13.44 million.

PAVmed drops 14% on launch of $13.4M direct offering